These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8490848)

  • 1. Correlation between morphologic and other prognostic markers of neuroblastoma. A study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the Pediatric Oncology Group.
    Joshi VV; Cantor AB; Brodeur GM; Look AT; Shuster JJ; Altshuler G; Larkin EW; Holbrook CT; Silverman JF; Norris HT
    Cancer; 1993 May; 71(10):3173-81. PubMed ID: 8490848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between morphologic and nonmorphologic prognostic markers of neuroblastoma.
    Joshi VV; Tsongalis GJ
    Ann N Y Acad Sci; 1997 Sep; 824():71-83. PubMed ID: 9382456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study.
    Bowman LC; Castleberry RP; Cantor A; Joshi V; Cohn SL; Smith EI; Yu A; Brodeur GM; Hayes FA; Look AT
    J Natl Cancer Inst; 1997 Mar; 89(5):373-80. PubMed ID: 9060959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study.
    Look AT; Hayes FA; Shuster JJ; Douglass EC; Castleberry RP; Bowman LC; Smith EI; Brodeur GM
    J Clin Oncol; 1991 Apr; 9(4):581-91. PubMed ID: 2066755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological variables in thoracic neuroblastoma: a Pediatric Oncology Group study.
    Morris JA; Shcochat SJ; Smith EI; Look AT; Brodeur GM; Cantor AB; Castleberry RP
    J Pediatr Surg; 1995 Feb; 30(2):296-302; discussion 302-3. PubMed ID: 7738754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [N-myc gene copies in children with neuroblastoma and its clinical significance].
    Ma XL; Gong LP; Zhou CJ; Zhang DW; Jin M; Wang HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1447-51. PubMed ID: 23257451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined determination of N-myc oncogene amplification and DNA ploidy in neuroblastoma. Complementary prognostic indicators.
    Muraji T; Okamoto E; Fujimoto J; Suita S; Nakagawara A
    Cancer; 1993 Nov; 72(9):2763-8. PubMed ID: 8402501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infants with metastatic neuroblastoma have improved survival with resection of the primary tumor.
    DeCou JM; Bowman LC; Rao BN; Santana VM; Furman WL; Luo X; Lobe TE; Kumar M
    J Pediatr Surg; 1995 Jul; 30(7):937-40; discussion 940-1. PubMed ID: 7472948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.
    Shimada H; Stram DO; Chatten J; Joshi VV; Hachitanda Y; Brodeur GM; Lukens JN; Matthay KK; Seeger RC
    J Natl Cancer Inst; 1995 Oct; 87(19):1470-6. PubMed ID: 7674334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Amplification of the N-myc cellular oncogene in neuroblastoma. Relation to other tumor markers].
    Verdona G; Garaventa A; Coviello DA; Cornaglia-Ferraris P; Tonini GP
    Boll Ist Sieroter Milan; 1986; 65(4):304-8. PubMed ID: 3790277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective study on amplification of N-myc and c-myc genes in pediatric solid tumors and its association with prognosis and tumor differentiation.
    Tsuda H; Shimosato Y; Upton MP; Yokota J; Terada M; Ohira M; Sugimura T; Hirohashi S
    Lab Invest; 1988 Sep; 59(3):321-7. PubMed ID: 3411933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of N-myc amplification with neuroblastoma: the Australian and New Zealand experience.
    Telford DJ; Kavallaris M; White L; Norris MD; Brian MJ; Stewart BW
    J Paediatr Child Health; 1992 Feb; 28(1):58-63. PubMed ID: 1554517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroblastoma: a single institution's experience with 128 children and an evaluation of clinical and biological prognostic factors.
    Lau L
    Pediatr Hematol Oncol; 2002 Mar; 19(2):79-89. PubMed ID: 11881792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
    Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
    J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study].
    Ladenstein R; Ambros PF; Urban C; Ambros IM; Fink FM; Zoubek A; Grienberger H; Schmitt K; Kerbl R; Horcher E; Amann G; Höfler G; Heinzl H; Gadner H; Mutz I
    Klin Padiatr; 1996; 208(4):210-20. PubMed ID: 8926686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
    Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
    Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum lactate dehydrogenase in childhood neuroblastoma. A Pediatric Oncology Group recursive partitioning study.
    Shuster JJ; McWilliams NB; Castleberry R; Nitschke R; Smith EI; Altshuler G; Kun L; Brodeur G; Joshi V; Vietti T
    Am J Clin Oncol; 1992 Aug; 15(4):295-303. PubMed ID: 1514525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas.
    Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J
    Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.